AzTrials
AzTrials

OsteoarthritisEAR2KNEENCT07755579

Effect of Autologous Ear Cartilage Micrografting in Knee Osteoarthritis

A study testing Mytocel MSK - Autologous Ear Cartilage Micrografting in people with Osteoarthritis and Osteoarthritis (OA) of the Knee, run by Regenera Activa Worldwide S.L. at 1 site in Hungary.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if a single injection of autologous cartilage micrografts suspension, obtained through processing with a specialized technology patient's own small piece of ear cartilage, can improve knee osteoarthritis in adult men and women aged 18-75 with confirmed moderate knee… Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
Mytocel MSK - Autologous Ear Cartilage Micrografting
Could I receive a placebo?
No, everyone receives an active treatment
How many people
33 participants
Where
1 siteHungary
Study dates
22 May 2023to 21 Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosed knee OA L-K grade II-III
  • Symptomatic knee OA (with pain)
  • Reduced mobility

Who cannot join

  • Knee OA L-K grade IV
  • Systemic Joint Disease (e.g. rheumatoid arthritis)
  • Active autoimmune disease
  • Active Oncologic process
  • If other orthobiologic treatments administered in the last 3 months

Trial locations and contacts

1 site in 1 country.

Hungary1 site
  • Semmelweis University

    Budapest, 1085

Other trials in Hungary

About this study

Official title: Effect of Autologous Cartilage Micrografting in Knee Cartilage Disease

The goal of this clinical trial is to learn if a single injection of autologous cartilage micrografts suspension, obtained through processing with a specialized technology patient's own small piece of ear cartilage, can improve knee osteoarthritis in adult men and women aged 18-75 with confirmed moderate knee osteoarthritis. The main questions it aims to answer are:

  • Does a single intra-articular injection of autologous ear-cartilage micrografts improve patients' clinical symptoms and knee function over 12 months?
  • What percentage of patients experience improvement in their complaints following treatment?
  • Do MRI scans show measurable improvement in knee cartilage condition 6 months after treatment?
  • Do inflammatory cytokine levels (IL-1β, IL-1α, IL-6, TNF-α) in joint fluid and cartilage tissue correlate with treatment response?
Read the detailed description

Background and Rationale Knee osteoarthritis is among the most common orthopedic conditions, affecting an estimated 10-12% of the population. Left untreated, it tends to progress, leading to worsening degenerative joint changes and functional loss. Treatment remains difficult because articular cartilage has very limited natural regenerative capacity. Currently used approaches - arthroscopic debridement, radiofrequency chondroplasty, and hyaluronic acid injection - have inconsistent or unsatisfactory efficacy.

This study reproduces a previously published treatment procedure using autologous cartilage micrografts sourced from the patient's own auricular (ear) cartilage, rather than from the knee joint itself or from cultured chondrocytes. Ear cartilage was selected as the donor tissue for three reasons: (1) elastic auricular cartilage has physical and biological properties closer to the hyaline cartilage found in the knee joint than other readily accessible cartilage sources; (2) the sampling procedure is simple and minimally invasive compared to harvesting from a weight-bearing joint; and (3) the perichondrial tissue surrounding ear cartilage contains a high density of chondroprogenitor cells responsible for regenerative processes.

Study Design The research has two components conducted on the same patient cohort: a clinical component evaluating the treatment's effect on patients' symptoms and joint imaging, and a laboratory component measuring inflammatory cytokine concentrations in tissue and joint fluid samples collected during the same procedure. This is a single-arm interventional study; there is no placebo or active comparator, and no randomization or blinding, since every enrolled participant receives the identical intervention on one knee affected by osteoarthritis.

Procedure

Each participant is treated on a single, affected knee. The procedure begins with drainage and storage of synovial fluid from the affected knee, for two reasons: synovial fluid in patients with knee osteoarthritis is expected to carry a high concentration of inflammatory cytokines that may impede improvement or contribute to discomfort, and removing it prevents dilution of the cartilage micrograft suspension subsequently injected.

Cartilage tissue is then harvested from the patient's own ear using a 2,5 mm dermatological punch - 3 biopsies maintaining a sterile field, under local anesthesia with lidocaine to ensure the harvesting is painless. The biopsies are placed inside a sterile medical disposable device class IIa (Rigeneracons RS) and 4 milliliters of sterile physiological saline are added to the harvested tissue. The device mechanically mills the cartilage into 80 microns micrografts thanks to Rigenera Technology - Mytocel MSK. This suspension is drawn into a syringe and delivered via a single anterolateral-approach injection directly into the synovial space of the osteoarthritic knee. The full procedure takes approximately 30 minutes and is considered as minimally invasive.

Cytokine Sub-Study For the laboratory component, a small aliquot (100 microliters) of the harvested ear cartilage suspension is frozen and stored (initially at -20°C, then at -80°C) at the time of tissue collection, before the remainder is injected. The synovial fluid drained from the knee prior to injection is handled and stored the same way. Concentrations of four cytokines associated with inflammation - IL-1β, IL-1α, IL-6, and TNF-α - are measured in both sample types. These measurements generate an individual inflammatory profile for each participant at baseline, which is then considered when interpreting each patient's clinical outcomes, on the hypothesis that a patient's baseline inflammatory state may influence how well they respond to treatment.

Basis for Expected Results A prior study using the same procedure and the same medical device reported successful interventions in all cases, with no wound-healing disorder or infection, no aesthetic deficit at the ear donor site, universal patient-reported pain relief and return to daily activity, significant improvement on clinical questionnaires, and an increase in lateral femoral condyle thickness on MRI performed at three years post-intervention. This study is designed to evaluate whether comparable outcomes are observed in the current knee osteoarthritis patient cohort.

Data Handling Data collection and processing are conducted solely for research purposes. Samples are processed anonymously using a code number system. A single technical record is maintained per participant, documenting all data, facts, and events relevant to or potentially influencing the study outcome. Code sheets linking code numbers to personal identifying data are kept in a locked file and separated from experimental data. Data are handled confidentially and are not shared with third parties. After processing, participant data are aggregated so that individuals cannot be identified from published results.

Statistical Analysis Outcome measures (KOOS subscales, including Pain and Symptoms/Stiffness; and Visual Analog Scale pain scores for current, worst, and best pain) were analyzed using repeated-measures ANOVA across five assessment timepoints (Baseline, Week 1, Month 3, Month 6, and Year 1) to test for an overall effect of visit/time. Mauchly's test of sphericity was applied to each outcome; where sphericity was violated, the Greenhouse-Geisser correction was used to adjust the degrees of freedom and significance values.

Where the overall visit effect was significant, simple contrasts compared each follow-up timepoint (Week 1, Month 3, Month 6, Year 1) against Baseline, with effect sizes reported as Cohen's d for each pairwise comparison. Descriptive statistics (mean, standard deviation, standard error, coefficient of variation) were reported for each timepoint.

Being tested
Mytocel MSK - Autologous Ear Cartilage Micrografting
Keywords
ear to knee, mytocel, mytocel msk, autologous micrografting, osteoarthritis, rigenera technology
Medical subject headings
Osteoarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mytocel MSK - Autologous Ear Cartilage MicrograftingDevice

    Also called Mytocel MSK, Autologous Micrografting, Rigenera Technology

    Autologous Ear Cartilage micrografting using Rigenera Technology - Mytocel MSK. A 2.5 mm punch biopsy of the patient's own auricular ear cartilage is harvested under local anesthesia. The tissue is mechanically disaggregated within the device after addition of 4mL sterile physiological saline, yielding a micrograft suspension containing autologous cartilage progenitor cells - without cell culture, expansion, or enzymatic digestion. The micrograft suspension is then delivered as a single intra-articular injection. The procedure is performed once per patient, on one knee, in a single outpatient session lasting approximately 30 minutes.

Study groups in NCT07755579
Study groupRoleWhat they receive
Intervention GroupOtherAutologous Cartilage Micrografting is performed to all subjects with moderate knee osteoarthritis
Receives: Device: Mytocel MSK - Autologous Ear Cartilage Micrografting

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Knee Osteoarthritis Outcome Score (KOOS)

    Change from baseline in KOOS subscale scores (including Pain and Symptoms/Stiffness), scored 0-100 with higher scores indicating better knee-related quality of life and function. Assessed via repeated-measures analysis across follow-up visits relative to baseline

    Measured: Baseline, 1 week, 3 months, 6 months, 12 months, and 24 months

Secondary outcomes (2)
  1. Change in knee cartilage thickness on MRI

    MRI-assessed change in knee joint cartilage structure (e.g., lateral femoral condyle thickness) following treatment.

    Measured: Baseline, 6 months

  2. Baseline synovial fluid and cartilage tissue cytokine concentrations

    Concentrations of IL-1β, IL-1α, IL-6, and TNF-α measured in synovial fluid and harvested ear cartilage tissue, used to generate an inflammatory profile for each participant at baseline.

    Measured: Time of the procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Aug 2026
  2. Study start22 May 2023
  3. Primary completion21 Dec 2025
  4. Study completion21 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
A disposable medical device used in regenerative medicine based treatment protocols
Masking
None (open label)
Enrolment
33 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07755579
Sponsor's protocol ID
MYTOCEL-KNEE-OA-052023
Other IDs
Official Research Registration, ref. BM/1298-3/2024, OGYÉI/67359-9/2023
Acronym
EAR2KNEE
Status last verified
Aug 2026
First submitted
4 Aug 2026
Last updated
10 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Mytocel MSK - Autologous Ear Cartilage Micrografting in people with Osteoarthritis and Osteoarthritis (OA) of the Knee, run by Regenera Activa Worldwide S.L. at 1 site in Hungary.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Hungary. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Knee Osteoarthritis Outcome Score (KOOS) (time frame: Baseline, 1 week, 3 months, 6 months, 12 months, and 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in